Biodiversitat de coleòpters i el seu paper com a plagues i com a agents de control biològic en un conreu de cítrics ecològics

El present treball estudiarà la comunitat d’espècies Coleoptera d’un camp de cítrics situat a la Selva de Camp, Tarragona, durant el període de temps dels anys 2002 fins al 2011. Els Coleoptera és l’ordre animal conegut comunament com els “escarabats” i és el més abundant i variat de tot el regne animal. Els estudis realitzats són pocs i, normalment, de les espècies més abundants (sobretot la família Coccinellidae). Totes les espècies d’aquest ordre presenten unes característiques típiques (García et al., 1989). (1) Presenten una cutícula dura, rígida i quitinitzada, amb el primer parell d’ales endurides (èlitres). Gran protecció als traumes físics. (2) Tenen una gran capacitat per retenir la humitat degut a que els estigmes s’obren els èlitres i eviten la pèrdua d’aigua per transpiració. (3) Presenten mandíbules mastegadores, adaptables i utilitzables per a una gran varietat de funcions (Chinery, 1988). (4) Algunes espècies poden acumular substàncies tòxiques a l’organisme. Presenten un règim alimentari fitòfag o micòfag, per norma general, tot i que també es poden trobar espècies sapròfagues o depredadores. És per aquest motiu que les espècies de Coleoptera podrien presentar un paper important com a potencial plagues o com a possible control biològic (Zahradnik, 1990). Durant moltes dècades, els plaguicides han constituït una lluita química contra les plagues dels cultius agrícoles, obtenint molt bons resultats en quant a manteniment i qualitat de les collites. No obstant, la seva utilització deliberada ha constituït en molts casos una important font de contaminació del territori. La seva gran mobilitat i persistència ha originat efectes de bioacumulació i biomagnificació a les xarxes tròfiques dels essers vius presents en aquestes zones. Actualment, per evitar tots aquests problemes ocasionats pels productes sintètics, el control biològic de plagues constitueix un dels principals pilars de la protecció moderna de cultius (Jacas et al., 2005). Se sap que les formigues tenen un doble rol molt important a les comunitats vegetals (poden ser mutualistes o depredadors generalistes), fent que la presència o absència d’aquestes pugui tenir efectes potencials sobre l’abundància d’altres artròpodes (James et al., 1999). És per aquest motiu que al present treball es realitzen experiments amb dos tipus d’arbres, els que presenten formigues i els que les formigues s’han exclòs experimentalment. Així doncs, els objectius del present treball són: - Descriure quantitativament la Comunitat de Coleoptera no Coccinellidae. - Descriure els canvis que s’han produït en la comunitat de Coleoptera al llarg de 10 anys. - Valorar la importància de les diferents espècies i/o famílies com a components de la biodiversitat d’un conreu ecològic. - Descriure els efectes sobre la comunitat de Coleoptera no Coccinellidae de la presència o absència de formgiues. - Valorar la importància de les diferents espècies i/o famílies com a possibles plagues o com a agents de control biològic.

The interior designer : Can the physiological agents of homeostasis create the appearance of design in nature?

Review of the book: The Tinkerer's Accomplice: How Design Emerges From Life Itself by J. Scott TurnerHarvard University Press: 2007. 304 pp.

Agents de salut a l’àmbit penitenciari

Actualment el grup d’Addiccions veu la necessitat de seguir abordant el consum de drogues als nostres centres des de l’educació per a la salut i la reducció de danys, però també des de la capacitació personal. Per tal que tot això sigui una realitat, partim de l’Enquesta Estatal sobre Drogues entre els Internats a Presó (ESDIP, 2006). Aquesta evidencia que, per una banda, actualment es duen a terme als centres penitenciaris pràctiques de risc d’infecció per VIH, tant pel que fa a conductes d’injecció, sexuals o de realització de tatuatges, però, per altra banda, també posa de manifest el pobre coneixement de les vies de transmissió de l’VIH/SIDA i de l’hepatitis C, molt sovint ple de mites i/o creences errònies. L’ESDIP destaca el consum o l’abús de les drogues com un factor previ i paral·lel a la presó. La relació entre presó i drogues es produeix en dos dimensions que sovint es confonen, ja que no solament hi ha un problema d’ordre penal sinó també d’ordre social. Per una part, els delictes comesos per un alt percentatge de la població penitenciària estan relacionats amb la venda i/o consum de substàncies il·legals; i, per una altra banda, un nombre elevat d’interns té problemes personals, socials i de salut associats al consum de drogues, des de la pròpia dependència a greus malalties. Els programes de reducció de danys que s’han dut a terme tradicionalment s’han d’adaptar als nous perfils de consumidor; a les noves drogues i a les diferents vies d’administració. S’ha de tenir present que la major part dels problemes associats a l’activitat delictiva són d’índole psicosocial i no es restringeixen als consums problemàtics. Entre els interns podem trobar persones fàcilment influenciables, que presenten baixa tolerància a la frustració, poca capacitat per generar alternatives en situacions de conflicte, dificultats per gestionar el temps d’oci, baixa o nul·la escolarització, mancances a nivell psicoafectiu,

Allergo-immunologie. 2. Faut-il se méfier des agents biologiques [Allergy-immunology. Do we have to be afraid of biological agents?].

Biologicals are now fully part of our daily therapeutic strategies. However, even if their high specificity seems to induce less risk compared to older or classical immunosuppressive drugs, there are not harmless especially regarding infectious but also immunological and allergic issues. Recent attempts to better characterize the different types of reactions to biologicals should be reported, allowing us better understanding of the risk to maintain these therapies or defining how to improve the methods to use them.

A Structural Analysis of the Health Expenditures and Portfolio Choices of Retired Agents

Richer and healthier agents tend to hold riskier portfolios and spend proportionally less on health expenditures. Potential explanations include health and wealth effects on preferences, expected longevity or disposable total wealth. Using HRS data, we perform a structural estimation of a dynamic model of consumption, portfolio and health expenditure choices with recursive utility, as well as health-dependent income and mortality risk. Our estimates of the deep parameters highlight the importance of health capital, mortality risk control, convex health and mortality adjustment costs and binding liquidity constraints to rationalize the stylized facts. They also provide new perspectives on expected longevity and on the values of life and health.

Immunosuppresseurs: usages systémiques et neurologiques [Systemic and neurological uses of immunosuppressive agents].

Involvement of the central or peripheral nervous system, frequently present in systemic inflammatory immune disorders, has to be considered a severe threat and requires aggressive immunosuppressive treatment to achieve rapid remission. This is usually obtained with high-dose systemic corticosteroids combined with cyclophosphamide. Once remission is obtained, immunosuppressive agents with a more favorable safety profile are needed to exert a corticosteroid-sparing effect and minimize adverse events. New therapeutic approaches are currently developed to treat autoimmune diseases, mostly linked to the definition of new indications for biological agents such as TNF-alpha antagonists and rituximab.

Disease activity in rheumatoid arthritis patients at initiation of biologic agents and 1 year of treatment: results from the Swiss SCQM registry.

OBJECTIVE: In Switzerland, the prescription of biologic antirheumatic agents in rheumatoid arthritis (RA) patients is not limited by stringent requirements from health authorities. The goals of this study were to: determine the characteristics of the Swiss patients at the initiation of biologics, compare them with other countries and evaluate whether different disease activity levels at initiation of therapy, resulting from distinct access to these treatment, influence their effectiveness. METHODS: This is a retrospective cohort study of RA patients followed in the Swiss register (SCQM-RA). Two thousand and sixty patients treated with biologics were retrieved. We present the disease characteristics and the patients' demographic data, at initiation and some effectiveness data after 1 year of treatment. RESULTS: Two thousand and sixty patients treated with biologics were retrieved. At initiation of treatment, the mean disease activity DAS (SD): 4.4 (1.4), number of previous antirheumatic treatments: 1.1, functional status HAQ: 1.1 (0.7) and median duration of illness: 5.5 years were significantly lower than in other published registries. The mean DAS: 3.3 (1.4) 1 year after initiation of therapy also appears lower than in other countries. Additionally, patients treated more recently (after 2005) had a significantly higher improvement in mean DAS. CONCLUSIONS: Data from the Swiss RA registry demonstrate that biologics are prescribed at a lower level of disease activity and after fewer prior DMARD failures than in most other countries, a practice that seems to correlate with overall lower absolute levels of disease activity and better patient outcomes after 1 year of treatment.

Novel Agents Targeting the IGF-1R/PI3K Pathway Impair Cell Proliferation and Survival in Subsets of Medulloblastoma and Neuroblastoma.

The receptor tyrosine kinase (RTK)/phosphoinositide 3-kinase (PI3K) pathway is fundamental for cancer cell proliferation and is known to be frequently altered and activated in neoplasia, including embryonal tumors. Based on the high frequency of alterations, targeting components of the PI3K signaling pathway is considered to be a promising therapeutic approach for cancer treatment. Here, we have investigated the potential of targeting the axis of the insulin-like growth factor-1 receptor (IGF-1R) and PI3K signaling in two common cancers of childhood: neuroblastoma, the most common extracranial tumor in children and medulloblastoma, the most frequent malignant childhood brain tumor. By treating neuroblastoma and medulloblastoma cells with R1507, a specific humanized monoclonal antibody against the IGF-1R, we could observe cell line-specific responses and in some cases a strong decrease in cell proliferation. In contrast, targeting the PI3K p110α with the specific inhibitor PIK75 resulted in broad anti-proliferative effects in a panel of neuro- and medulloblastoma cell lines. Additionally, sensitization to commonly used chemotherapeutic agents occurred in neuroblastoma cells upon treatment with R1507 or PIK75. Furthermore, by studying the expression and phosphorylation state of IGF-1R/PI3K downstream signaling targets we found down-regulated signaling pathway activation. In addition, apoptosis occurred in embryonal tumor cells after treatment with PIK75 or R1507. Together, our studies demonstrate the potential of targeting the IGF-1R/PI3K signaling axis in embryonal tumors. Hopefully, this knowledge will contribute to the development of urgently required new targeted therapies for embryonal tumors.

Agents and intermediaries

Managing Football is the first book to directly respond to the rapid managerial, commercial and global development of the sport and offers a thorough analysis of how the football industry can meet the challenges that flow from these developments. Expertly edited by two well known specialists in football business management, it draws together the work of a world-class contributor team to form a comprehensive analysis of the most important issues facing the managers of football businesses across the world. The cutting edge analysis examines all the important business challenges in the football industry and the management of football businesses and covers all of the key football markets including England, Spain, France, Italy, Germany, Australia, North America, China, South Africa, South Korea, the Netherlands & Belgium, and Mexico. Managing Football is simply a must-read for anyone studying or working in football business management and is set to be an important landmark in this rapidly moving and globally expansive field.

Current multiple myeloma treatment strategies with novel agents: a European perspective.

The treatment of multiple myeloma (MM) has undergone significant developments in recent years. The availability of the novel agents thalidomide, bortezomib, and lenalidomide has expanded treatment options and has improved the outcome of patients with MM. Following the introduction of these agents in the relapsed/refractory setting, they are also undergoing investigation in the initial treatment of MM. A number of phase III trials have demonstrated the efficacy of novel agent combinations in the transplant and nontransplant settings, and based on these results standard induction regimens are being challenged and replaced. In the transplant setting, a number of newer induction regimens are now available that have been shown to be superior to the vincristine, doxorubicin, and dexamethasone regimen. Similarly, in the front-line treatment of patients not eligible for transplantation, regimens incorporating novel agents have been found to be superior to the traditional melphalan plus prednisone regimen. Importantly, some of the novel agents appear to be active in patients with high-risk disease, such as adverse cytogenetic features, and certain comorbidities, such as renal impairment. This review presents an overview of the most recent data with these novel agents and summarizes European treatment practices incorporating the novel agents.

Les connectivites: progrès thérapeutiques et place de la biothérapie [Connective tissue diseases: news in therapy, role of biologics agents].

Systemic lupus erythematosus and primary Sjögren's syndrom are the two major connective tissue diseases. A better knowledge of their physiopathology allows us today to propose an adapted therapy. Moreover progress concerns the oldest treatment, hydroxychloroquine, and biotherapy. Hydroxychloroquine is still an actual treatment for lupus, its positive effects are better understood today. Nevertheless it does not seem to be efficient to treat primitive Sjögren. Biotherapy targeting B lymphocytes seems efficient in these two connective tissue diseases. Anti TNF therapy is not recommended and seems to induce connective tissue diseases. The real news is the recent approval and reimbursement in Switzerland of the new drug belimumab (Benlysta) in case of moderate lupus.